Universal CAR Construction Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

At Creative Biolabs, with more than two decades of relentless dedication to advancing biotechnology, we are proud to introduce our cutting-edge Universal CAR Construction Service. This service represents a paradigm shift in CAR-T therapy, offering an array of innovative solutions to the myriad challenges faced by traditional CAR-T approaches.

Universal CAR Design

Figure 1. Biotin-Binding Immune Receptors. (Sutherland, et al., 2020)

Biotin-Binding Immune Receptors

Biotin-Binding Immune Receptors are Universal CARs engineered to recognize biotin-labeled antigens. This design allows for a remarkable degree of flexibility, as a wide variety of biotinylated molecules, including antibodies and ligands, can be used as targeting agents. By enabling the targeting of multiple antigens with a single CAR construct, Biotin-Binding Immune Receptors expand the scope of CAR-T therapy and make it more adaptable to a range of malignancies.

Figure 2. Anti-FITC CAR. (Sutherland, et al., 2020)

Anti-FITC CAR

Anti-FITC CARs are designed to target antigens labeled with fluorescein isothiocyanate (FITC). FITC is commonly used in research and diagnostics, and the Anti-FITC CAR technology harnesses this convenience for therapeutic purposes. This Universal CAR type demonstrates the potential for personalized therapy by adapting the CAR construct to specific FITC-labeled targets, offering a novel approach to precision medicine.

Figure 3. Leucine Zipper (SUPRA) CAR. (Sutherland, et al., 2020)

Leucine Zipper (SUPRA) CAR

Leucine Zippers are structural motifs that allow for the dimerization of proteins. In the context of CAR-T therapy, Leucine Zippers CARs employ this principle to create CAR constructs that can dimerize upon antigen recognition. This feature enhances the signal strength and activation of CAR-T cells, potentially improving their efficacy in combating cancer. The Leucine Zippers CAR design exemplifies the innovative strategies employed at Creative Biolabs to enhance CAR-T cell function.

Figure 4. Convertible CAR. (Sutherland, et al., 2020)

Convertible CAR

Convertible CARs are a groundbreaking innovation designed to enhance CAR-T therapy's safety and specificity. These CARs can be toggled on and off using small molecules or other inducible mechanisms. This reversibility provides an extra layer of control, enabling CAR-T cell activation when needed and deactivation to mitigate adverse effects, such as cytokine release syndrome (CRS). The Convertible CAR technology is a testament to Creative Biolabs' commitment to improving CAR-T therapy's safety profile.

Figure 5. SNAP CAR. (Sutherland, et al., 2020)

SNAP CAR

SNAP (S‐O6‐alkylguanine-DNA alkyltransferase) CARs introduce a novel method for tagging and tracking CAR-T cells. The SNAP CAR system allows for the site-specific and irreversible binding of a synthetic ligand to the CAR-T cell surface. This technology has applications in tracking the persistence and biodistribution of CAR-T cells in patients, providing valuable insights into the therapy's dynamics and optimizing treatment strategies.

Figure 6. Co-LOCKR CAR. (Sutherland, et al., 2020)

Co-LOCKR CAR

Co-LOCKR CARs are designed with a unique conditional activation mechanism that relies on synthetic oligomerization domains. This feature provides precise control over CAR-T cell activation, making it possible to fine-tune the immune response against cancer. Co-LOCKR CARs exemplify the commitment of Creative Biolabs to advancing the field through innovative engineering.

Figure 7. Anti-5B9 Tag CAR. (Sutherland, et al., 2020)

Anti-5B9 Tag CAR

The Anti-5B9 Tag CAR represents a remarkable development in CAR-T therapy targeting tagged antigens. With the ability to recognize 5B9-tagged antigens, this Universal CAR type enhances the versatility of CAR-T therapy by offering an efficient and adaptable way to target a broad spectrum of tumor-associated molecules.

Figure 8. Anti-PNE CAR. (Sutherland, et al., 2020)

Anti-PNE CAR

The Anti-PNE CAR is designed to target PNE (peptide nucleic acid–peptide nucleic acid hybridization) tagged antigens. This innovative approach leverages the unique properties of PNE to create a highly specific and effective CAR-T therapy. The Anti-PNE CAR technology adds another powerful tool to the arsenal of CAR-T therapy options.

Figure 9. SpyTag/SpyCatcher CAR. (Sutherland, et al., 2020)

SpyTag/SpyCatcher CAR

SpyTag, a small peptide sequence, and SpyCatcher, an engineered protein recognizing specific antigens, form an irreversible bond, ensuring highly specific and stable antigen recognition, precise CAR-T cell activation, extended therapeutic effects, and versatile adaptability. This innovative approach holds immense promise in precision medicine, revolutionizing CAR-T therapy by enhancing safety, efficacy, and treatment options for a diverse array of cancers, solid tumors, and challenging antigen profiles.

After the development of the universal CAR (Chimeric Antigen Receptor), our team of scientists is ready to provide you with a comprehensive range of research services. These services encompass, but are not limited to, CAR cell in vitro assays, CAR preclinical in vivo assays, and CAR clinical trials.

Creative Biolabs, leveraging our CAR development platform and cutting-edge technologies, boasts extensive expertise in universal CAR construction. Our standardized pipeline ensures the rapid and high-quality production of CARs. Furthermore, our CAR platform services can be customized to cater to your specific research requirements. Not only are our services cost-effective, but they also offer a high level of reliability. For further information about our services, please reach out to us via email, and our dedicated team will promptly respond to your inquiries.

Reference

Sutherland, A.R.; et al. Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting. Int. J. Mol. Sci. 2020, 21, 7222.